^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^Feild JA, Zhang L, Brun KA, Brooks DP, Edwards RM (May 1999). "Cloning and functional characterization of a sodium-dependent phosphate transporter expressed in human lung and small intestine". Biochemical and Biophysical Research Communications. 258 (3): 578–582. doi:10.1006/bbrc.1999.0666. PMID10329428.
^Xu H, Bai L, Collins JF, Ghishan FK (December 1999). "Molecular cloning, functional characterization, tissue distribution, and chromosomal localization of a human, small intestinal sodium-phosphate (Na -Pi) transporter (SLC34A2)". Genomics. 62 (2): 281–284. doi:10.1006/geno.1999.6009. PMID10610722.
^Clinical trial number NCT05329545 for "Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)." at ClinicalTrials.gov
Xu H, Collins JF, Bai L, Kiela PR, Ghishan FK (March 2001). "Regulation of the human sodium-phosphate cotransporter NaP(i)-IIb gene promoter by epidermal growth factor". American Journal of Physiology. Cell Physiology. 280 (3): C628–C636. doi:10.1152/ajpcell.2001.280.3.C628. PMID11171583. S2CID7439508.
Xu H, Uno JK, Inouye M, Collins JF, Ghishan FK (February 2005). "NF1 transcriptional factor(s) is required for basal promoter activation of the human intestinal NaPi-IIb cotransporter gene". American Journal of Physiology. Gastrointestinal and Liver Physiology. 288 (2): G175–G181. doi:10.1152/ajpgi.00396.2004. PMID15458926. S2CID14194207.
Izumi S, Miyazawa H, Ishii K, Uchiyama B, Ishida T, Tanaka S, et al. (February 2007). "Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis". American Journal of Respiratory and Critical Care Medicine. 175 (3): 263–268. doi:10.1164/rccm.200609-1274OC. PMID17095743.